We are rapidly translating our specific, efficient and versatile CRISPR/Cas9 gene-editing platform into therapies to treat hemoglobinopathies, cancer, diabetes and other diseases. Our multi-disciplinary team of world-class researchers and drug developers works every day to translate our CRISPR/Cas9 technology into breakthrough human therapeutics. Our lead program targeting the blood diseases β-thalassemia and sickle cell disease has entered clinical testing, as has our first allogeneic CAR-T program targeting B-cell malignancies. We are also advancing additional blood stem cell, immuno-oncology, regenerative medicine and in vivo programs towards the clinic. Source
No articles found.
We are a vertically integrated, clinical stage gene therapy company with four ongo...
We are a vertically integrated, clinical stage ...
Premier operates one of the nationâs largest performance improvement alliances o...
Premier operates one of the nationâs largest ...
Coloplast develops products and services that make life easier for people with ver...
Coloplast develops products and services that m...
Eniware, LLC provides portable, power-independent medical instrument sterilization...
Eniware, LLC provides portable, power-independe...
EpigenCare is connecting consumers with skincare companies through a direct-to-con...
EpigenCare is connecting consumers with skincar...
Apollo Endosurgery, Inc. is a medical device company focused on less invasive ther...
Apollo Endosurgery, Inc. is a medical device co...
Join the National Investor Network and get the latest information with your interests in mind.